Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 5, 2003, Pages 1116-1121

  Gyllfors, Pär ^a   Bochenek, Grazyna ^b   Overholt, John ^c   Drupka, Diane ^d   Kumlin, Maria ^e   Sheller, James ^c   Nizankowska, Ewa ^b   Isakson, Peter C ^d   Mejza, Filip ^b   Lefkowith, James B ^d   Dahlén, Sven Erik ^e   Szczeklik, Andrew ^b   Murray, John J ^c   Dahlén, Barbro ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PFIZER INC   (United States)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Aspirin intolerance; Asthma; COX 2; Cyclooxygenase inhibition; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; CELECOXIB; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GLUCOCORTICOID; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; THEOPHYLLINE;

ADULT; AGED; ANALGESIA; ARTICLE; ASTHMA; BIOCHEMISTRY; BRONCHOSPASM; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROVOCATION TEST; SIDE EFFECT; SYMPTOM; URINARY EXCRETION;

EID: 0038066532     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.1450     Document Type: Article

References (28)

1. Szczeklik A, Stevenson DD. Aspirin-induced asthma: advances in pathogenesis and management. J Allergy Clin Immunol 1999;104:5-13.
2. Szczeklik A, Gryglewski RJ, Czemiawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975;1:67-9.
3. Raud J, Dahlén SE, Sydbom A, Lindbom L, Hedqvist P. Enhancement of acute allergic inflammation by indomethacin is reversed by prostaglandin E2: apparent correlation with in vivo modulation of mediator release. Proc Natl Acad Sci U S A 1988:85:2315-9.
4. Hartert TV, Dworski RT, Mellen BG, Oates JA, Murray JJ, Sheller JR. Prostaglandin E2 decreases allergen-stimulated release of prostaglandin D2 in airways of subjects with asthma. Am J Respir Crit Care Med 2000;162:637-40.
5. Smith WL, Langenbach R. Why there are two cyclooxygenase isozymes. J Clin Invest 2001;107:1491-5.
6. Scott LJ, Lamb HM. Rofecoxib. Drugs 1999;58:499-507.
7. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis. rheumatoid arthritis and acute pain. Drugs 2000:59:957-80.
8. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs non-steroidal antiinflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study, a randomized controlled trial. JAMA 2000;284:1247-55.
9. Bjarnason I, Rainsford KD. COX-2 inhibitors and the gastrointestinal tract [letter]. Gut 2001;48:451.
10. Fries JF. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;341:1397-9.
11. Vane JR, Bakhle YS, Butting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998:38:97-120.
12. Dahlén B, Boréus LO, Anderson P. Andersson R, Zetterström O. Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocations in aspirin-sensitive subjects. Allergy 1994;49:43-9.
13. Andri L, Senna G, Betteli C, Givanni S, Scaricabarozzi I, Mezzelani P, et al. Tolerability of nimesulide in aspirin-sensitive patients. Ann Allergy 1994:72:29-32.
14. Bavbek S, Celik G, Ediger D, Mungan D, Demirel YS, Misirligil Z. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance. J Asthma 1999;36:657-63.
15. Kosnik M, Music E, Matjaz F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998;53:1231-3.
16. Dahlén B, Szczeklik A, Murray JJ. Celecoxib in patients with asthma and aspirin intolerance [letter]. N Engl J Med 2001:344:142.
17. Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, et al. Urinary leukotriene E4 concentrations increase after ASA challenge in ASA-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025-9.
18. Kumlin M, Dahlén B, Björck T, Zetterström O, Granström E, Dahlén SE. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to bronchial provocations with allergen, aspirin, leukotriene D4, and histamine in asthmatics. Am Rev Respir Dis 1992:146:96-103.
19. Dahlén B, Kumlin M, Margolskee DJ. Larsson C, Blomqvist H, Williams VC, et al. The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by bronchial provocation with lysine-aspirin in aspirin-sensitive asthmatics. Eur Respir J 1993;6:1018-26.
20. Nizankowska E, Bestynska-Krypel A. Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000;15:863-9.
21. Kumlin M, Stensvad F, Larsson L, Dahlén B, Dahlén S-E. Validation and application of a new simple strategy for measurements of leukotriene E4 in human urine. Clin Exp Allergy 1995;25:467-79.
22. FitzGerald AG, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001;345:433-42.
23. Yoshida S, Ischizaki Y, Onuma K. Shoji T. Nakagawa H, Amayasu H. Selective cyclo-oxygenase 2 inhibitor in patients with aspirin-induced asthma. J Allergy Clin Immunol 2000;106:1201-2.
24. Szczeklik A. Nizankowska E. Bochenek G, Nagraba K, Mejza F. Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001:31:219-25.
25. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47-51.
26. Stevenson DD. Simon RA. Aspirin sensitivity: respiratory and cutaneous manifestations. In: Middleton E, Reed CE. Ellis EF, Adkinson NF, Younginger JW, eds. Allergy: principles and practice. St Louis: Mosby; 1988. p. 1537-58.
27. Sfinches Borges M, Capriles-Hulett A, Caballero-Fonsenca F, Pérez CR. Tolerability of new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001:87:201-4.
28. Schellenberg RR, Isserow SH. Anaphylactoid reaction to a cyclooxygenase-2 inhibitor in a patient who had a reaction to a cyclooxygenase-1 inhibitor. N Engl J Med 2001;345:1856.